全文获取类型
收费全文 | 1275169篇 |
免费 | 94084篇 |
国内免费 | 1984篇 |
专业分类
耳鼻咽喉 | 18185篇 |
儿科学 | 42257篇 |
妇产科学 | 37812篇 |
基础医学 | 186984篇 |
口腔科学 | 35380篇 |
临床医学 | 108103篇 |
内科学 | 251432篇 |
皮肤病学 | 26497篇 |
神经病学 | 99170篇 |
特种医学 | 49982篇 |
外国民族医学 | 366篇 |
外科学 | 197584篇 |
综合类 | 26513篇 |
现状与发展 | 1篇 |
一般理论 | 300篇 |
预防医学 | 92580篇 |
眼科学 | 29056篇 |
药学 | 97757篇 |
1篇 | |
中国医学 | 2496篇 |
肿瘤学 | 68781篇 |
出版年
2018年 | 11809篇 |
2015年 | 11610篇 |
2014年 | 15994篇 |
2013年 | 24343篇 |
2012年 | 33541篇 |
2011年 | 35935篇 |
2010年 | 21206篇 |
2009年 | 20013篇 |
2008年 | 34973篇 |
2007年 | 37940篇 |
2006年 | 38498篇 |
2005年 | 37791篇 |
2004年 | 36376篇 |
2003年 | 35367篇 |
2002年 | 34917篇 |
2001年 | 58093篇 |
2000年 | 59584篇 |
1999年 | 50687篇 |
1998年 | 14232篇 |
1997年 | 12809篇 |
1996年 | 13071篇 |
1995年 | 12345篇 |
1994年 | 11758篇 |
1993年 | 10860篇 |
1992年 | 40984篇 |
1991年 | 40358篇 |
1990年 | 39885篇 |
1989年 | 38706篇 |
1988年 | 36108篇 |
1987年 | 35350篇 |
1986年 | 33723篇 |
1985年 | 32134篇 |
1984年 | 23922篇 |
1983年 | 20818篇 |
1982年 | 12377篇 |
1981年 | 10927篇 |
1980年 | 10204篇 |
1979年 | 22635篇 |
1978年 | 15877篇 |
1977年 | 13730篇 |
1976年 | 12970篇 |
1975年 | 14201篇 |
1974年 | 16682篇 |
1973年 | 16076篇 |
1972年 | 15318篇 |
1971年 | 14229篇 |
1970年 | 13214篇 |
1969年 | 12731篇 |
1968年 | 11978篇 |
1967年 | 10478篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Michael E Egger Joanna M Ohlendorf Charles R Scoggins Kelly M McMasters Robert C G Martin II 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2015,17(9):839-845
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery. 相似文献
53.
54.
55.
56.
57.
58.
59.
60.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献